Mendus - Multi-front progression during FY22 : vimarsana.com

FY22 was marked by several clinical milestones for Mendus, notably the positive survival data from the Phase II ADVANCE II study in acute myeloid leukaemia (AML) and encouraging safety data from the ongoing

Related Keywords

Dennis Riedl , , Mendus , Ulti , Front , Progression , During , Y22 ,